A new study finds an experimental drug that is significant for PD treatment " A large team of researchers from Denali Therapeutics, working with colleagues from multiple entities in the U.S. and one in Canada, has found that a LRRK2 inhibitor called DNL201 showed no ill effects to volunteers in a clinical trial. The researchers found that administration of the drug brought down levels of LRRK2 enzymes and also showed no signs of the side-effects that had been seen in some other animals." Study Notes .
I read it a couple times and remain confusedPathogenic mutations in the LRRK2 gene . Did volunteers without mutation in this gene also show improvement ? How does one determine if they have such a mutation ? You23and me , I suppose.
I was tested through the MJFF in conjunction with the University of Indiana as well as through my movement disorders clinic. Alternatively 23andme shows that variant
The molecule specifically targets the enzyme overactivity caused by the LRRK2 mutation but it turns out that LRRK2 is overactive as well in idiopathic PD patients who don't have the mutation so it's hoped that the molecule will be broadly useful. I'm excited.
A new study record has been posted on the Clinical Trials website.
Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants With Parkinson's Disease and Pathogenic LRRK2 Variants
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Drug fails in Phase II trial for treating Parkinson's Disease - Exenatide (Byetta, Bydureon)
Terazosin for Parkinson's Disease (TZ-PD) Trial
Ambroxol in Parkinson's: Results of Phase ll Trial Published
Clinical trial
